CANCERS BRONCHIQUES NON A PETITES CELLULES NON METASTATIQUES NON RESECABLES |
|
|
référence |
traitement |
n |
% RO |
p |
survie médiane |
survie à 3 ans |
p |
|
Berghmans, 2009
(1) |
CDDP-Gemci+VNR + 66 Gy |
|
|||||
|
I. En induction |
21 |
57 % |
|
|
|
NS |
|
|
II. En consolidation |
28 |
79 % |
|
|
|||
|
Senan, 2011
(2) I |
CDDP-docétaxel + RT (66 Gy) |
|
|||||
|
I. En induction |
26 |
|
|
|
|
|
|
|
II. En consolidation |
34 |
|
Non atteint |
|
|||
|
Garrido, 2013
(3) |
Gemcitabine + docétaxel + 60GY |
|
|
|
|
|
NS |
|
I. En induction |
68 |
57 % |
NS |
|
30 % |
||
|
II. En consolidation |
67 |
56 % |
|
20 % |
|||
Références
(1) Berghmans T, Van Houtte P., Paesmans M, Giner V, Lecomte J, Koumakis G, et al. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer 2009 May;64(2):187-93.
(2) Senan S, Cardenal F, Vansteenkiste J, Stigt J, Akyol F, De NW, et al. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol 2011 Mar;22(3):553-8.
(3) Garrido P, Rosell R, Arellano A, Andreu F, Domine M, Perez-Casas A, et al. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study. Lung Cancer 2013 Jul;81(1):84-90.